1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : BIOTECH
  4. CELLDEX THERAPEUTICS INC.
Celldex Therapeutics Inc.
XNAS: CLDX
Download real time
28.25-1.18(-4.01%)
37.42% Fall from 52W High
1.9M
XNAS Volume

XNAS 13 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Celldex Therapeutics Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Celldex Therapeutics Inc share price target, revenues, EPS, net income and more

Celldex Therapeutics Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • NEGATIVE

    Quarterly Revenue Celldex Therapeutics Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of -97.0% YoY.

  • NEGATIVE

    Quarterly Net Profit Celldex Therapeutics Inc Jun-2026 Quarterly Net Profit is $-74 Million which is growth of -29.9% YoY.

Celldex Therapeutics Inc., Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
000.10.70.71.23.22.50.24.11.50.3
Cost Of Rev.
-------------
Gross Profit
-------------
⌄
80.684.587.373.664.663.457.255.348.840.839.342.833.5
Operating Profit
-80.6-84.4-87.2-73.6-63.9-62.7-56-52.1-46.3-40.6-35.1-41.2-33.2
⌄
-------------
Profit Before Tax
-73.5-78.7-81.3-67-56.6-53.8-47.1-42.1-35.8-32.8-43.3-38.3-30.5
Tax
-------------
⌄
-73.5-78.7-81.3-67-56.6-53.8-47.1-42.1-35.8-32.8-43.3-38.3-30.5
Diluted NI Avail to Com Stockholders Ann.
-73.5-78.7-81.3-67-56.6-53.8-47.1-42.1-35.8-32.8-43.3-38.3-30.5
Basic EPS
-0.9-1.2-1.2-1-0.9-0.8-0.7-0.6-0.5-0.6-0.8-0.8-0.7
Diluted EPS After ExtraOrdinary
-1-1.3-1.3-1.1-1-0.9-0.8-0.8-0.7-0.7-0.7-0.9-0.7
Number Of Shares End
77.866.666.566.466.466.466.466.36658.952.147.347.3
Net Income Continuing Discontinued Operations
-73.5-78.7-81.3-67-56.6-53.8-47.1-42.1-35.8-32.8-43.3-38.3-30.5
Normalized Income
-65.1-70.2-72.4-58.2-47.4-44.5-37.3-32.5-28.2-25.6-23.6-31.1-25.3
Interest Income
-------------
Interest
-------------
Net Interest Income
-------------
EBIT
-73.5-78.7-81.3-67-56.6-53.8-47.1-42.1-35.8-32.8-43.3-38.3-30.5
EBITDA
-72.6-77.8-80.5-66.2-55.7-52.9-46.3-41.3-35.1-32-42.6-37.5-29.8
Reconciled Cost Of Rev.
-------------
Reconciled Depr.
0.90.90.80.80.90.90.80.80.80.80.80.80.8
Profit From Continuing Operations
-73.5-78.7-81.3-67-56.6-53.8-47.1-42.1-35.8-32.8-43.3-38.3-30.5
Normalized EBITDA
-86.8-89.3-92.2-79.4-70.2-70.8-64.1-61.3-56-47.6-26.2-43.5-35.2
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Celldex Therapeutics Inc competitor comparison and performance snapshot within industry

Celldex Therapeutics Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Annual Revenue Celldex Therapeutics Inc Dec-2025 Annual Revenue is $2 Million which is growth of -78.0% YoY.

  • NEGATIVE

    Annual Net Profit Celldex Therapeutics Inc Dec-2025 Annual Net Profit is $-259 Million which is growth of -63.9% YoY.

Celldex Therapeutics Inc., Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
-14.5%
-27.3%
 1.576.92.44.77.43.69.512.76.85.5
Cost Of Rev. Ann.
-
-
 ----------
Gross Profit Ann.
-
-
 ----------5.5
Operating Exp. Ann.
38.2%
38.3%
326288.9202.1148.9109.573.85758.185.9122.1139.7135
Operating Profit Ann.
-
-
-325.8-287.4-195.1-142-107.1-69.2-49.6-54.5-76.4-109.3-132.9-129.5
⌄
-
-
 ----------
Other Exp. Ann.
-
-
 28.637.20.6-5.2-1.6-11.43.7-75.5-84.42.3
PBT Ann.
-
-
-300.5-258.8-157.9-141.4-112.3-70.7-61-50.9-152-117.3-128.5-127.2
Tax Ann.
-
-
 ---0.2-1.2-0.8-24.3--
⌄
-
-
-300.5-258.8-157.9-141.4-112.3-70.5-59.8-50.9-151.2-93-128.5-127.2
Diluted NI Avail to Com Stockholders Ann.
-
-
-300.5-258.8-157.9-141.4-112.3-70.5-59.8-50.9-151.2-93-128.5-127.2
EPS Ann.
-
-
 -3.9-2.5-2.9-2.4-1.6-2-3.5-14.5-10.8-19.1-19.7
Diluted EPS Ann.
-
-
 -3.9-2.5-2.9-2.4-1.6-2-3.5-14.5-10.8-19.1-19.7
Number Of Shares End
12.2%
10.9%
 66.566.452.147.146.739.716.511.69.17.26.6
Total Exp. Ann.
38.2%
38.3%
 288.9202.1148.9109.573.85758.185.9122.1139.7135
Net Income Continuing Discontinued Operations Ann.
-
-
-300.5-258.8-157.9-141.4-112.3-70.5-59.8-50.9-151.2-93-128.5-127.2
Normalized Income Ann.
-
-
-265.9-222.5-123.6-105-88.6-59.5-42.5-45.8-61.8-73.6-113.1-114.4
Interest Income Ann.
-
-
 -----------
Interest Ann.
-
-
 ----------
EBITDA Ann.
-
-
-297.2-255.4-154.7-138.4-109.4-67.7-57-46-148.2-112-124.4-123.2
Reconciled Cost Of Rev. Ann.
-
-
 ----------
Reconciled Depr. Ann.
5.4%
-2.7%
3.43.43.232.93.13.94.93.85.34.14
Profit From Continuing Operations Ann.
-
-
-300.5-258.8-157.9-141.4-112.3-70.5-59.8-50.9-151.2-93-128.5-127.2
Normalized EBITDA Ann.
-
-
-347.7-312.6-229.1-139.7-99-64.5-34.3-53.32.9-96-133.2-125.5
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
-78.6%
2Y CAGR
-53.4%
3Y CAGR
-14.5%
5Y CAGR
-27.3%
7Y CAGR
-23.2%
10Y CAGR
-12.2%
Total Revenue Annual is falling faster than historical averages.
Operating Exp. Ann.
1Y CHG
42.9%
2Y CAGR
39.3%
3Y CAGR
38.2%
5Y CAGR
38.3%
7Y CAGR
18.9%
10Y CAGR
7.9%
Operating Expenses Annual Cr growth is higher than historical averages.

Celldex Therapeutics Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Total Shareholders Fund Celldex Therapeutics Inc Dec-2025 Total Shareholders Fund is $527 Million which is growth of -29.4% YoY.

  • NEGATIVE

    Total Assets Celldex Therapeutics Inc Dec-2025 Total Assets is $583 Million which is growth of -26.4% YoY.

Celldex Therapeutics Inc., Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
18.2%
19.8%
583792.3465.6352.7444.7235.8122.9155.8315.6383.4337.6
⌄
28.2%
16.1%
55.845.336.526.525.226.528.931.879.3117.947.5
⌄
17.4%
20.3%
527.2747429.2326.2419.5209.494124.1236.4265.4290.1
Total Capitalization Ann.
17.4%
20.3%
527.2747429.2326.2419.5209.494124.1236.4265.4290.1
Tangible Assets Ann.
18.7%
22.8%
500719.8402299392.3178.745.375.477.893260.4
Working Capital Ann.
17.4%
21.4%
483.7707.7400.6299.1394.3183.655.186.5117160.4264.7
Invested Capital Ann.
17.4%
20.3%
527.2747429.2326.2419.5209.494124.1236.4265.4290.1
Tangible Book Value Ann.
18.7%
22.8%
500719.8402299392.3178.745.375.477.893260.4
Borrowings Ann.
-16.8%
-8.1%
2.33.82.5433.53.7----
Net Debt Ann.
-
-
-----------
Share Issued Ann.
12.2%
11%
66.666.455.947.246.739.617129.286.6
Number Of Shares End
12.2%
10.9%
66.566.452.147.146.739.716.511.69.17.26.6
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
-26.4%
2Y CAGR
11.9%
3Y CAGR
18.2%
5Y CAGR
19.8%
7Y CAGR
20.7%
10Y CAGR
5.6%
Total Assets Annual is falling faster than historical averages.
Total Current Liabilities Ann.
1Y CHG
29.1%
2Y CAGR
28.1%
3Y CAGR
40%
5Y CAGR
29.1%
7Y CAGR
22.1%
10Y CAGR
5.4%
Total Current Liabilities Annual Cr growth is stable compared to historical averages.
Total ShareHolders Funds Ann.
1Y CHG
-29.4%
2Y CAGR
10.8%
3Y CAGR
17.4%
5Y CAGR
20.3%
7Y CAGR
23%
10Y CAGR
6.2%
Total ShareHolders Funds Annual is falling faster than historical averages.

Celldex Therapeutics Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Book Value Per Share Celldex Therapeutics Inc Book Value Per Share is $8 which is growth of -29.6% YoY.

  • NEUTRAL

    ROE Celldex Therapeutics Inc ROE is 0% which is growth of 0% YoY.

Celldex Therapeutics Inc., Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
RoA Ann. %
-
-
--25.10%-34.56%-28.17%-20.72%-33.32%-36.51%-64.14%-26.62%-35.66%-43.44%
ROE Ann. %
-
-
--26.84%-37.45%-30.13%-22.43%-39.41%-46.66%-83.89%-37.08%-46.27%-50.70%
ROIC %
-
-
--6.1-12.7-7.8-4.7-9.8-10.3-7.5-1.7-13.4-10.7
OPM Ann. %
-
-
-18,599.81%-2,778.89%-2,063.66%-4,543.74%-1,486.73%-668.27%-1,526.03%-801.05%-857.94%-1,958.68%-2,363.89%
Inventory Turnover Ratio Ann.
-
-
-----------
Asset Turnover Ann. %
-
-
-0000000000
Working Capital Turnover Ann.
-
-
000000.10.10.100
Quick Ratio Ann.
-
-
-18.413.716.424.713.85.67.75.15.49.6
Current Ratio Ann.
-
-
-18.913.917.124.913.95.77.95.25.69.8
Interest Coverage Ratio Ann.
-
-
-----------
LT Debt To Equity Ann.
-
-
-000----
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Celldex Therapeutics Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Cash From Operating Activity Celldex Therapeutics Inc Dec-2025 Cash From Operating Activity is $-211 Million which is growth of -33.7% YoY.

  • POSITIVE

    Net Cash Flow Celldex Therapeutics Inc Dec-2025 Net Cash Flow is $1 Million which is growth of 108.0% YoY.

Celldex Therapeutics Inc., Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
-
-
-210.9-157.8-107.3-103.7-60.9-40.4-46.4-75.2-99.9-113-98.9
⌄
32.5%
-
209.1-290.1-105.889.9-216.2-98.217.129.846.568.9-50.2
⌄
-16.3%
-57.4%
2.4441.5218.54.1272.4171.216.329.451.314.5193.2
Cash Plus Cash Eqv. End Of Year Ann.
-0.6%
-8%
28.928.434.829.439.143.811.224.340.342.572.1
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-56.6%
0.5-6.55.4-9.7-4.732.6-13.1-16-2.2-29.744.1
Cash Plus Cash Eqv. Begin Of Year Ann.
-10.1%
20.5%
28.434.829.439.143.811.224.340.342.572.128
Income Tax Paid Supplemental Data Ann.
-
-
-----------
Interest Paid Supplemental Data Ann.
-
-
----------
Capex Ann.
-
-
-2.7-1.9-1.8-1.8-1.3-1.6-0.7-0.8-1.8-2.8-4.9
Issuance Of Capital Stock Ann.
17%
92.6%
432.3216.2269.9170.816.3295114188.8
Issuance Of Debt Ann.
-
-
---3-----
Repayment Of Debt Ann.
-
-
----3----
Repurchase Of Capital Stock Ann.
-
-
-----------
Free Cash Flow Ann.
-
-
-213.7-159.7-109.1-105.6-62.2-42-47.2-76.1-101.7-115.8-103.8
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Investing Act. Ann.
3Y CAGR
32.5%
7Y CAGR
32.1%
Cash from Investing Activity Annual growth is stable compared to historical averages.
Cash from Financing Act. Ann.
1Y CHG
-99.5%
2Y CAGR
-89.5%
3Y CAGR
-16.3%
5Y CAGR
-57.4%
7Y CAGR
-30.1%
10Y CAGR
-35.5%
Cash from Financing Annual Activity is falling faster than historical averages.
×